Smell dysfunction in COVID-19 patients : More than a yes-no question
Copyright © 2020 Elsevier B.V. All rights reserved..
Anosmia has been recognized as a prevalent and early symptom by many COVID-19 patients. However, most researchers have recorded smell dysfunction solely as present or absent and based on subjective evaluation by patients. We described the results of 57 consecutive COVID-19 patients seen at FIOCRUZ, Rio de Janeiro, Brazil, from April to May 2020. Data about the presence of smell loss, the onset of smell loss and other COVID-19 symptoms such as ageusia and nasal congestion or rhinorrhea were recorded. All patients at the initial consultation and 34 healthy controls underwent the Q-SIT, which is a quick disposable three-item smell identification test, by a trained physician. We compared three groups: healthy controls, COVID+ patients with reported smell loss (COVID w/ SL) and COVID+ patients without smell loss (COVID+ w/o SL). The mean age of patients was 41.4 years (SD ± 10.4), and 54.4% were women. Smell loss was reported by 40.4% of COVID-19 patients. We observed a gradual effect with higher Q-SIT scores in healthy controls, followed by COVID+ w/o SL and COVID+ w/ SL (medians = 3, 2 and 0; respectively, p < 0.001). Anosmia or severe microsmia (Q-SIT≤1) was present in 11.1% (CI: 3.1%-26.1%) of controls, 32.4% (CI: 17.4%-50.5%) of COVID-19 w/o SL and 87% (CI: 66.4%-97.2%) of COVID+ w/ SL (p < 0.001). This study provides evidence that olfactory dysfunction in COVID-19 is common and more prevalent than what is perceived by patients. Q-SIT is a quick and reliable screening test for the detection of smell dysfunction during the pandemics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:418 |
|---|---|
| Enthalten in: |
Journal of the neurological sciences - 418(2020) vom: 15. Nov., Seite 117107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lima, Marco A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 04.12.2020 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jns.2020.117107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314399224 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314399224 | ||
| 003 | DE-627 | ||
| 005 | 20231225152637.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jns.2020.117107 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314399224 | ||
| 035 | |a (NLM)32866813 | ||
| 035 | |a (PII)S0022-510X(20)30444-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lima, Marco A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Smell dysfunction in COVID-19 patients |b More than a yes-no question |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Anosmia has been recognized as a prevalent and early symptom by many COVID-19 patients. However, most researchers have recorded smell dysfunction solely as present or absent and based on subjective evaluation by patients. We described the results of 57 consecutive COVID-19 patients seen at FIOCRUZ, Rio de Janeiro, Brazil, from April to May 2020. Data about the presence of smell loss, the onset of smell loss and other COVID-19 symptoms such as ageusia and nasal congestion or rhinorrhea were recorded. All patients at the initial consultation and 34 healthy controls underwent the Q-SIT, which is a quick disposable three-item smell identification test, by a trained physician. We compared three groups: healthy controls, COVID+ patients with reported smell loss (COVID w/ SL) and COVID+ patients without smell loss (COVID+ w/o SL). The mean age of patients was 41.4 years (SD ± 10.4), and 54.4% were women. Smell loss was reported by 40.4% of COVID-19 patients. We observed a gradual effect with higher Q-SIT scores in healthy controls, followed by COVID+ w/o SL and COVID+ w/ SL (medians = 3, 2 and 0; respectively, p < 0.001). Anosmia or severe microsmia (Q-SIT≤1) was present in 11.1% (CI: 3.1%-26.1%) of controls, 32.4% (CI: 17.4%-50.5%) of COVID-19 w/o SL and 87% (CI: 66.4%-97.2%) of COVID+ w/ SL (p < 0.001). This study provides evidence that olfactory dysfunction in COVID-19 is common and more prevalent than what is perceived by patients. Q-SIT is a quick and reliable screening test for the detection of smell dysfunction during the pandemics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Central nervous system viral diseases | |
| 650 | 4 | |a Olfaction disorders | |
| 700 | 1 | |a Silva, Marcus Tulius T |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira, Raquel V |e verfasserin |4 aut | |
| 700 | 1 | |a Soares, Cristiane N |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Crissi L |e verfasserin |4 aut | |
| 700 | 1 | |a Azevedo, Anna E |e verfasserin |4 aut | |
| 700 | 1 | |a Moraes, Raissa L |e verfasserin |4 aut | |
| 700 | 1 | |a Rezende, Rafaela B |e verfasserin |4 aut | |
| 700 | 1 | |a Chagas, Ingrid T |e verfasserin |4 aut | |
| 700 | 1 | |a Espíndola, Otávio |e verfasserin |4 aut | |
| 700 | 1 | |a Leite, Ana Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Araujo, Abelardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the neurological sciences |d 1964 |g 418(2020) vom: 15. Nov., Seite 117107 |w (DE-627)NLM000061956 |x 1878-5883 |7 nnns |
| 773 | 1 | 8 | |g volume:418 |g year:2020 |g day:15 |g month:11 |g pages:117107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jns.2020.117107 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 418 |j 2020 |b 15 |c 11 |h 117107 | ||